Dr. James Larrick is a biomedical entrepreneur with an international reputation in biotechnology. He has developed expertise in cytokines, therapeutic antibodies, molecular biology, and pharmaceutical drug development over his thirty-five-year career, and he has written or co-authored nine books, published over 300 papers/chapters, and submitted more than fifty patents.

Dr. Larrick earned his M.D. and Ph.D. from Duke University as a graduate of the prestigious Medical Scientist Training Program. After completing his medical house-staff training at Stanford University, Dr. Larrick contributed to the development of the first therapeutic human monoclonal antibodies for cancer and infectious diseases as a postdoctoral research fellow in the Stanford Cancer Biology Research Labs. He built upon this work as a founding scientist of Cetus Immune Research Labs, which he led during the 1980s culminating in the identification and clinical advancement into Phase 3 of human monoclonal antibodies for sepsis. Based on this work, Dr. Larrick has initiated and led a number of antibody development projects, out-licensed to several major pharma companies, e.g. Takeda, Roche, Amgen, etc.

In 1991, Dr. Larrick founded the Panorama Research Institute (PRI), a biopharmaceutical translational organization that he continues to lead to this day. Dr. Larrick’s PRI team has discovered and initiated the development of a diverse and innovative portfolio of pharmaceutical molecules addressing major unmet needs in cancer, infectious, autoimmune, cardiovascular, neurological and metabolic diseases. PRI has incubated over twenty life science projects/companies, including legacy start-ups: Kalobios Inc., Galaxy Biotechnology Inc., NuGen Technology Inc., Adamas Inc., and Absalus Inc. (now Teva). PRI has also co-founded two companies in Europe: PanGenetics b.v. (Abbvie) and TargetQuest b.v. (Dyax). To date, PRI-initiated projects and/or companies have led to seven IPOs/exits. Recent work at PRI has focused on Applied Healthspan Engineering -- the utilization of advances in molecular medicine to preserve well-being as we age. Genetic Engineering News (GEN) has recognized Dr. Larrick as a “Top Serial Bio Entrepreneur” over multiple years.

Currently, he continues his roles at PRI and Life Science Angels, and serves on the boards of several biotechnology companies (e.g. Eumentis Therapeutics, https://www.eumentistx.com/) as well as chair of the SAB of AutoBahn Labs and Wuxi Biologics.